Immuno-Biological LaboratoriesImmuno-Biological Laboratories Co., Ltd.4570東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Immunity Related | +11.2%5y | 634-2.4% | 7918.9% | 81313.3% | 96421.6% | 1,00228.1% |
| Cosmetics | -28.3%5y | 13-94.1% | 4-331.9% | 4-91.3% | 522.6% | 3-22.7% |
| Gene recombination silkworm Development | — | — | — | — | — | — |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第44期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第43期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第42期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第41期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第40期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
訂正有価証券報告書－第39期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 46 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.